Poxel Announces its Participation at Investor Conferences in October 2021
30 September 2021 - 8:30AM
Business Wire
Regulatory News:
POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage
biopharmaceutical company developing innovative treatments for
chronic serious diseases with metabolic pathophysiology, including
non-alcoholic steatohepatitis (NASH) and rare disorders, today
announced its participation at upcoming investor conferences in
October 2021.
- HealthTech Innovation Days Conference – France Biotech -
Paris, France (virtual) Date: October 4-5 Thomas Kuhn,
CEO of Poxel, and Anne Renevot, CFO, will be available for
one-on-one virtual meetings.
- H.C. Wainwright 5th Annual NASH Conference (virtual)
Date: October 12 Members of the Poxel management team will
present Poxel’s two NASH clinical-stage candidates, PXL770 and
PXL065, and will be available for one-on-one virtual meetings.
PXL770 is a first-in-class, oral direct adenosine
monophosphate-activated protein kinase (AMPK) activator. PXL065 is
a novel, oral, proprietary deuterium-stabilized R-stereoisomer of
pioglitazone.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company developing
innovative treatments for chronic serious diseases with metabolic
pathophysiology, including non-alcoholic steatohepatitis (NASH) and
rare disorders. Poxel has clinical and earlier-stage programs from
its adenosine monophosphate-activated protein kinase (AMPK)
activator and deuterated thiazolidinedione (D-TZD) platforms
targeting chronic and rare metabolic diseases. For the treatment of
NASH, PXL065 (deuterium-stabilized R-pioglitazone) is in a
streamlined Phase 2 trial (DESTINY-1). PXL770, a first-in-class
direct AMPK activator, has successfully completed a Phase 2a
proof-of-concept trial for the treatment of NASH, which met its
objectives. For the rare inherited metabolic disorder, X-linked
adrenoleukodystrophy (ALD), the company intends to initiate Phase
2a proof of concept studies with PXL065 and PXL770 in patients with
adrenomyeloneuropathy (AMN). TWYMEEG® (Imeglimin), Poxel’s
first-in-class lead product that targets mitochondrial dysfunction,
has been approved and launched for the treatment of type 2 diabetes
in Japan. Poxel expects to receive sales-based payments and
royalties from Sumitomo Dainippon Pharma. Poxel has a strategic
partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan,
China, South Korea, Taiwan and nine other Southeast Asian
countries. The Company intends to generate further growth through
strategic partnerships and pipeline development. Listed on Euronext
Paris, Poxel is headquartered in Lyon, France, and has subsidiaries
in Boston, MA, and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210929005940/en/
Poxel SA Catherine David Investor Relations &
Communication Manager catherine.david@poxelpharma.com +33 7 64 57
61 78
Aurélie Bozza Investor Relations & Communication Director
aurelie.bozza@poxelpharma.com +33 6 99 81 08 36
Elizabeth Woo Senior Vice President, Investor Relations &
Communication elizabeth.woo@poxelpharma.com
Investor relations / Media - EU/US Trophic Communications
Stephanie May or Valeria Fisher poxel@trophic.eu +49 171 185 56 82
or +49 175 804 1816
Investor relations / Media - France NewCap Emmanuel Huynh
or Arthur Rouillé poxel@newcap.eu +33 1 44 71 94 94
Poxel (EU:POXEL)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Poxel (EU:POXEL)
Historical Stock Chart
Von Apr 2023 bis Apr 2024